Autologous Hematopoietic Stem Cell Transplantation as a Potential Treatment for Multiple Sclerosis Patients
Alexa McCune
Abstract
Multiple Sclerosis is a severe autoimmune disorder in which the central nervous system is targeted, specifically the myelin sheath. Due to the neurodegeneration of the myelin sheath in both the brain and spinal cord, symptoms of numbness, lack of muscle coordination, and chronic fatigue are seen. Multiple Sclerosis has a devastating effect on the immune system as it causes an attack the body’s own cells. Although there is currently no cure for MS, there are several treatment options available that work to improve the quality of life for affected individuals, including the use of various immunosuppressant drugs. Research suggests that there may be an alternative treatment plan which involves the use of an autologous Hematopoietic Stem Cell Transplant. Autologous HSCT has shown to halt the progression of the disease as well as reduce clinical relapses. However, it is yet to become a fully practiced procedure due to various safety concerns as well as the lack of a successful animal model. Further research on the use of autologous HSCT may help to treat Multiple Sclerosis in the future.
